Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.

ABSTRACT:

SUBMITTER: Bhave M 

PROVIDER: S-EPMC12829183 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature